Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients

Imagem de Miniatura
Arquivos
art_GUIMARAES_Effects_of_shortterm_addon_ezetimibe_to_statin_treatment_2017.PDF (477.4 KB)
Citações na Scopus
6
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
GUIMARAES, Elizandra Silva
CERDA, Alvaro
BERNIK, Marcia Martins Silveira
FAJARDO, Cristina Moreno
HIRATA, Mario Hiroyuki
HIRATA, Rosario Dominguez Crespo
Citação
CARDIOVASCULAR THERAPEUTICS, v.35, n.6, article ID UNSP e12307, 8p, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
AimThe influence of short-term add-on ezetimibe to simvastatin treatment on expression of adipokines and inflammatory markers was investigated in diabetic and nondiabetic patients with hypercholesterolemia. MethodHypercholesterolemic nondiabetic (HC, n=37) and diabetic (DM, n=47) patients were treated with simvastatin (SV, 10 or 20mg/d/8-wk) and then SV plus ezetimibe (SV+EZ, 10mg each/d/4wk). Serum lipids, glycemic profile, and inflammatory markers (hsCRP, adiponectin, resistin, VCAM-1, and ICAM-1) were evaluated before and after the add-on ezetimibe therapy. mRNA expression of ADIPOR1, ADIPOR2, RETN, VCAM1, and ICAM1 was measured by real-time PCR in peripheral blood mononuclear cells (PBMC). ResultsSerum concentrations of LDL and HDL cholesterol, and adiponectin were higher in HC than DM patients (P<.05). The add-on ezetimibe therapy reduced total and LDL cholesterol, apoB and adiponectin serum levels in HC and DM groups, and resistin in HC subjects (P<.05). DM patients showed higher expression of ADIPOR1, ADIPOR2, RETN, and VCAM1 in PBMC than subjects in HC group, before and after add-on ezetimibe therapy (P<.05). PBMC RETNmRNA expression was reduced by add-on ezetimibe therapy in HC individuals (P<.05), but not in DM subjects. ConclusionShort-term add-on ezetimibe to simvastatin treatment suppressing effects on hypercholesterolemia and adiponectinemia is independent of the diabetes status. Resistin serum levels and leukocyte mRNA expression are influenced by add-on ezetimibe to statin treatment.
Palavras-chave
Adipokines, Diabetes, Dyslipidemia, Ezetimibe, Inflammatory markers, mRNA expression, Statin
URI
https://observatorio.fm.usp.br/handle/OPI/24511
Referências
  1. Arsenault BJ, 2016, AM J CARDIOL, V118, P494, DOI 10.1016/j.amjcard.2016.05.044
  2. Cerda A, 2015, CARDIOVASC THER, V33, P168, DOI 10.1111/1755-5922.12126
  3. Kater ALD, 2010, METABOLISM, V59, P921, DOI 10.1016/j.metabol.2010.02.011
  4. Derosa G, 2016, VASC HEALTH RISK MAN, V12, P415, DOI 10.2147/VHRM.S64460
  5. Dolezelova E, 2017, BRIT J CLIN PHARMACO, V83, P1380, DOI 10.1111/bcp.13250
  6. Federici M, 2015, ATHEROSCLEROSIS SUPP, V17, P17, DOI 10.1016/S1567-5688(15)50005-6
  7. Ferreira AM, 2017, AM J CARDIOVASC DRUG, V17, P169, DOI 10.1007/s40256-016-0205-0
  8. Filippatos TD, 2017, EXPERT REV CLIN PHAR, V10, P187, DOI 10.1080/17512433.2017.1263565
  9. Friedman HS, 2011, CLIN THER, V33, P212, DOI 10.1016/j.clinthera.2011.02.011
  10. Gouni-Berthold I, 2008, CLIN ENDOCRINOL, V68, P536, DOI 10.1111/j.1365-2265.2007.03080.x
  11. Grosso AF, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-47
  12. Gupta M, 2010, J CARDIOVASC PHARM, V56, P241, DOI 10.1097/FJC.0b013e3181e7fd74
  13. Hernandez-Mijares A, 2016, ATHEROSCLEROSIS, V247, P40, DOI 10.1016/j.atherosclerosis.2016.01.044
  14. Jamaluddin MS, 2012, BRIT J PHARMACOL, V165, P622, DOI 10.1111/j.1476-5381.2011.01369.x
  15. Joksic J, 2016, CLIN EXP PHARMACOL P, V43, P22, DOI 10.1111/1440-1681.12503
  16. Khavandi M, 2017, CURR CARDIOL REP, V19, DOI 10.1007/s11886-017-0818-1
  17. Kishimoto Miyako, 2011, J Med Invest, V58, P86, DOI 10.2152/jmi.58.86
  18. Koh KK, 2015, INT J CARDIOL, V199, P126, DOI 10.1016/j.ijcard.2015.07.016
  19. Krysiak R, 2012, J INTERN MED, V271, P32, DOI 10.1111/j.1365-2796.2011.02394.x
  20. Krysiak R, 2015, ENDOKRYNOL POL, V66, P114, DOI 10.5603/EP.2015.0017
  21. Krysiak R, 2014, CARDIOVASC THER, V32, P40, DOI 10.1111/1755-5922.12057
  22. Li LL, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0004-7
  23. Libby P, 2010, J NUCL MED, V51, p33S, DOI 10.2967/jnumed.109.069633
  24. Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
  25. Minder CM, 2013, CURR OPIN CARDIOL, V28, P554, DOI 10.1097/HCO.0b013e32836429e6
  26. Nakamura K, 2014, J CARDIOL, V63, P250, DOI 10.1016/j.jjcc.2013.11.006
  27. Naruse R, 2015, OBES RES CLIN PRACT, V9, P67, DOI 10.1016/j.orcp.2014.02.001
  28. Nu baumer B, 2016, DTSCH ARZTEBL INT, V113, P445
  29. Park H, 2011, J GASTROENTEROL, V46, P101, DOI 10.1007/s00535-010-0291-8
  30. Rosen JB, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0075-5
  31. Rotella CM, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-80
  32. Satoh M, 2015, CLIN SCI, V129, P93, DOI 10.1042/CS20150027
  33. Takase S, 2017, ARTERIOSCL THROM VAS, V37, P350, DOI 10.1161/ATVBAHA.116.308388
  34. Tamaki N, 2012, J ATHEROSCLER THROMB, V19, P532
  35. Tamura Y, 2012, J ATHEROSCLER THROMB, V19, P608
  36. Tobaru T, 2013, HEART VESSELS, V28, P39, DOI 10.1007/s00380-012-0243-8
  37. Toth PP, 2016, AM J CARDIOL, V118, P1812, DOI 10.1016/j.amjcard.2016.08.071
  38. Tsiotra PC, 2008, MEDIAT INFLAMM, DOI 10.1155/2008/892864
  39. Yu Chih-Chieh, 2012, BMC Res Notes, V5, P251, DOI 10.1186/1756-0500-5-251
  40. Zafrir B, 2014, CARDIOVASC DRUG THER, V28, P361, DOI 10.1007/s10557-014-6534-9
  41. Zinellu A, 2016, J PHARMACEUT BIOMED, V129, P383, DOI 10.1016/j.jpba.2016.07.025

Coleções
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - ODS/03